Endocrine Abstracts

Introduction: MTC is a rare neuroendocrine tumor arising from thyroid parafollicular cells. After initial treatment, patients should be divided according to their clinical status in cured, biochemical persistence (BIO) and structural persistence (STR) of the disease. Concerning BIO patients less is known about the structural disease appearance rate and the time elapsed between the first evaluation after surgery and the appearance of structural disease.Me...

Background: Since 2006 according to the European consensus for the management of patients with DTC, in tumors ≤ 1 cm, treatment with thyroidectomy alone without 131I treatment was suggested. Therefore, in our institution, we applied this suggestion in clinical practice, although prospective studies were not still available. Aim of this study is to evaluate the rate of the events occurring in a medium-long term follow-up.Patients and Meth...

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

Objectives: Pregnant women with type 1 diabetes (T1D) are associated with an increased risk of maternal fetal complications. Continuous subcutaneous insulin infusion [CSII] has been shown to improve metabolic control and perinatal morbidity. Few studies have compared the use of CSII with SAP (sensor augmented pump) therapy to flash glucose monitoring (FSL) in pregnant women with T1D. We aim to evaluate the possible differences between both monitoring systems associated with CS...

Introduction: Brown tumor or osteitis fibrocystica is a benign bone lesion reflecting an abnormality of bone metabolism in the context of hyperparathyroidism. It can affect the entire skeleton, including the pelvis, ribs, clavicles and extremities. Involvement of the maxillary bone is very uncommon. We present a case of multiple brown tumors with an unusual maxillo-mandibular localization, revealed by a disorder of phosphocalcic metabolism and tertiary hyperparathyroidism. Thi...

Introduction: Paragangliomas are rare tumors originated from extraadrenals chromaffin cells. Most are sporadic, but between 30% and 50% are associated with hereditary syndromes. Mutations in the succinate gene dehydrogenase (SDH) have been identified as a cause of the hereditary paraganglioma-pheochromocytoma syndrome.Material and methods: Descriptive study of case series of patients belonging to the Southern Health Area of Seville with mutations in the ...

Introduction: An increased Body Mass Index (BMI) has been associated with higher prevalence of many cancers, including differentiated thyroid cancer. However, no data have been reported about potential impact of BMI on aggressiveness of presentation and clinical outcome of medullary thyroid cancer (MTC).Aim: To evaluate the potential influence of BMI on clinical presentation and outcome of MTC.Methods: We reviewed anthropometric an...

Introduction: Digestive neuroendocrine tumors (DNETs) represent a heterogeneous group of tumors. This heterogeneity is manifested by the variable localization of these tumors but also by a great clinical and biological diversity. Thus, they occupy an increasingly important place in digestive oncology.NETs are very rare and represent about 1% of all digestive tumors, due to their slow evolution. The majority of them develop in the digestive tract (67.5%) ...

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...

Introduction: Pasireotide long acting release (LAR) is approved for second line treatment of acromegaly. We present 3 patients with aggressive acromegaly treated with a personalized de-escalation approach.Case 1: A 61-year-old female affected by acromegaly reisistant on first-line SSAs. In 2015 therapy was switched to pasireotide LAR 60 mg every 28 days. After two years, the IGF-I level touched the lower age range and therapy was downscaled to pasireotid...